TY - JOUR
T1 - Rituximab identified as an independent risk factor for severe PJP
T2 - A case-control study
AU - Zalmanovich, Anat
AU - Ben-Ami, Ronen
AU - Rahav, Galia
AU - Alon, Danny
AU - Moses, Allon
AU - Olshtain-Pops, Karen
AU - Weinberger, Miriam
AU - Shitrit, Pnina
AU - Katzir, Michal
AU - Gottesman, Bat Sheva
AU - Chowers, Michal
N1 - Publisher Copyright:
© 2020 Zalmanovich et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2020/9
Y1 - 2020/9
N2 - Objective Pneumocystis jirovecii pneumonia (PJP) was reported among immunosuppressed patients with deficits in cell-mediated immunity and in patients treated with immunomodulatory drugs. The aim of this study was to identify risk-factors for PJP in noninfected HIV patients. Methods This retrospective, test negative, case-control study was conducted in six hospitals in Israel, 2006–2016. Cases were hospitalized HIV-negative patients with pneumonia diagnosed as PJP by bronchoalveolar lavage. Controls were similar patients negative for PJP. Results Seventy-six cases and 159 controls were identified. Median age was 63.7 years, 65% males, 34% had hematological malignancies, 11% inflammatory diseases, 47% used steroids and 9% received antilymphocyte monoclonal antibodies. PJP was independently associated with antilymphocyte monoclonal antibodies (OR 11.47, CI 1.50–87.74), high-dose steroid treatment (OR 4.39, CI 1.52–12.63), lymphopenia (OR 8.13, CI 2.48–26.60), low albumin (OR 0.15, CI 0.40–0.54) and low BMI (OR 0.80, CI 0.68–0.93). Conclusion In conclusion, rituximab, which is prescribed for a wide variety of malignant and inflammatory disorders, was found to be significant risk-factor for PJP. Increased awareness of possible PJP infection in this patient population is warranted.
AB - Objective Pneumocystis jirovecii pneumonia (PJP) was reported among immunosuppressed patients with deficits in cell-mediated immunity and in patients treated with immunomodulatory drugs. The aim of this study was to identify risk-factors for PJP in noninfected HIV patients. Methods This retrospective, test negative, case-control study was conducted in six hospitals in Israel, 2006–2016. Cases were hospitalized HIV-negative patients with pneumonia diagnosed as PJP by bronchoalveolar lavage. Controls were similar patients negative for PJP. Results Seventy-six cases and 159 controls were identified. Median age was 63.7 years, 65% males, 34% had hematological malignancies, 11% inflammatory diseases, 47% used steroids and 9% received antilymphocyte monoclonal antibodies. PJP was independently associated with antilymphocyte monoclonal antibodies (OR 11.47, CI 1.50–87.74), high-dose steroid treatment (OR 4.39, CI 1.52–12.63), lymphopenia (OR 8.13, CI 2.48–26.60), low albumin (OR 0.15, CI 0.40–0.54) and low BMI (OR 0.80, CI 0.68–0.93). Conclusion In conclusion, rituximab, which is prescribed for a wide variety of malignant and inflammatory disorders, was found to be significant risk-factor for PJP. Increased awareness of possible PJP infection in this patient population is warranted.
UR - http://www.scopus.com/inward/record.url?scp=85090843283&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0239042
DO - 10.1371/journal.pone.0239042
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 32915907
AN - SCOPUS:85090843283
SN - 1932-6203
VL - 15
JO - PLoS ONE
JF - PLoS ONE
IS - 9 September
M1 - e0239042
ER -